Please select the option that best describes you:
Do you discontinue an aromatase inhibitor in a patient if they have a cardiac event while on the drug?
Does the presence of other cardiac risk factors change your recommendation?
Answer from: Medical Oncologist at Academic Institution
Randomized clinical trials and several meta-analyses that compared tamoxifen with aromatase inhibitors (Khosrow-Khavar et al., PMID 32065766 is a more recent one) demonstrated statistically significant increase in the rate of cardiovascular events in women taking aromatase inhibitors although the ab...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
The decision to continue or discontinue endocrine therapy in a patient with breast cancer needs to take into account the dynamic interplay with other comorbidities and competing causes of mortality.
It’s not so much whether an AI is contributing to the cardiac event, which is less likel...